JP2020509780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509780A5 JP2020509780A5 JP2019552206A JP2019552206A JP2020509780A5 JP 2020509780 A5 JP2020509780 A5 JP 2020509780A5 JP 2019552206 A JP2019552206 A JP 2019552206A JP 2019552206 A JP2019552206 A JP 2019552206A JP 2020509780 A5 JP2020509780 A5 JP 2020509780A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- stem cell
- genetically engineered
- hla
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022160907A JP7731579B2 (ja) | 2017-03-20 | 2022-10-05 | 細胞並びにその使用方法及び製造方法 |
| JP2025134751A JP2025169335A (ja) | 2017-03-20 | 2025-08-13 | 細胞並びにその使用方法及び製造方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473564P | 2017-03-20 | 2017-03-20 | |
| US62/473,564 | 2017-03-20 | ||
| PCT/US2018/023288 WO2018175390A1 (en) | 2017-03-20 | 2018-03-20 | Cells and methods of uses and making the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022160907A Division JP7731579B2 (ja) | 2017-03-20 | 2022-10-05 | 細胞並びにその使用方法及び製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020509780A JP2020509780A (ja) | 2020-04-02 |
| JP2020509780A5 true JP2020509780A5 (enExample) | 2021-04-30 |
Family
ID=63585747
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552206A Pending JP2020509780A (ja) | 2017-03-20 | 2018-03-20 | 細胞並びにその使用方法及び製造方法 |
| JP2022160907A Active JP7731579B2 (ja) | 2017-03-20 | 2022-10-05 | 細胞並びにその使用方法及び製造方法 |
| JP2025134751A Pending JP2025169335A (ja) | 2017-03-20 | 2025-08-13 | 細胞並びにその使用方法及び製造方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022160907A Active JP7731579B2 (ja) | 2017-03-20 | 2022-10-05 | 細胞並びにその使用方法及び製造方法 |
| JP2025134751A Pending JP2025169335A (ja) | 2017-03-20 | 2025-08-13 | 細胞並びにその使用方法及び製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200095543A1 (enExample) |
| EP (1) | EP3601528A4 (enExample) |
| JP (3) | JP2020509780A (enExample) |
| CN (2) | CN110637083A (enExample) |
| AU (2) | AU2018239320B2 (enExample) |
| CA (1) | CA3094322A1 (enExample) |
| WO (1) | WO2018175390A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| WO2018102612A1 (en) | 2016-12-02 | 2018-06-07 | Juno Therapeutics, Inc. | Engineered b cells and related compositions and methods |
| CN109234232A (zh) * | 2018-09-30 | 2019-01-18 | 杭州华安单抗生物技术有限公司 | 兔外周血b细胞的培养体系及培养方法、抗体的制备方法和应用 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| EP4007596A1 (en) | 2019-08-01 | 2022-06-08 | Sana Biotechnology, Inc. | Dux4 expressing cells and uses thereof |
| JP7728747B2 (ja) | 2019-08-23 | 2025-08-25 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ２４発現細胞およびそれらの用途 |
| WO2021072302A1 (en) * | 2019-10-10 | 2021-04-15 | New York Stem Cell Foundation, Inc. | Modified stem cells and methods of use thereof |
| WO2021102324A1 (en) * | 2019-11-20 | 2021-05-27 | Vita Therapeutics, Inc. | Method of engineering hypoimmunogenic muscle precursor cells |
| EP4125961A1 (en) * | 2020-03-25 | 2023-02-08 | Sana Biotechnology, Inc. | Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions |
| CN111548998B (zh) * | 2020-04-23 | 2022-08-05 | 中山大学 | 一种分泌pd-1抗体的长寿浆细胞及其制备方法与应用 |
| IL297636A (en) * | 2020-04-27 | 2022-12-01 | Sana Biotechnology Inc | Repeat dosing of hypoimmunogenic cells |
| CN111849909A (zh) * | 2020-06-03 | 2020-10-30 | 暨南大学 | 一种用于快速高效扩增人b淋巴细胞体外扩增的细胞及其构建方法 |
| WO2021251271A1 (ja) * | 2020-06-09 | 2021-12-16 | 帝人株式会社 | Ｍｈｃ－クラスｉ発現が抑制された細胞 |
| CN114015656A (zh) * | 2020-07-15 | 2022-02-08 | 南京北恒生物科技有限公司 | 用于同种异体移植的工程化免疫细胞 |
| CA3181118A1 (en) * | 2020-07-15 | 2022-01-20 | Yali ZHOU | Engineered immune cell for allotransplantation |
| CN114457024A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| US11965022B2 (en) | 2020-12-31 | 2024-04-23 | Sana Biotechnology, Inc. | Methods and compositions for modulating CAR-T activity |
| US20240269181A1 (en) * | 2021-05-20 | 2024-08-15 | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences | Method for regenerating humoral immunity system and use thereof |
| CN114181968B (zh) * | 2022-02-11 | 2022-07-19 | 北京干细胞与再生医学研究院 | 一种具备b谱系分化潜能的人造血祖细胞的制备方法及其应用 |
| EP4479084A1 (en) | 2022-02-14 | 2024-12-25 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| EP4547825A1 (en) | 2022-07-01 | 2025-05-07 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
| CN116008564B (zh) * | 2023-01-09 | 2025-07-22 | 中南大学湘雅二医院 | 检测2-nbdg阳性b细胞的试剂在制备诊断和/或预后自身免疫糖尿病制剂中的应用 |
| WO2024169917A1 (zh) * | 2023-02-16 | 2024-08-22 | 士泽生物医药（苏州）有限公司 | 通用型细胞及其制备方法 |
| WO2024238387A1 (en) * | 2023-05-12 | 2024-11-21 | Nkmax Co., Ltd. | Method of treating alzheimer's disease with expanded natural killer cells |
| EP4735585A1 (en) | 2023-06-30 | 2026-05-06 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
| WO2025096757A1 (en) | 2023-11-01 | 2025-05-08 | Sana Biotechnology, Inc. | Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5573940A (en) * | 1989-06-12 | 1996-11-12 | Oklahoma Medical Research Foundation | Cells expressing high levels of CD59 |
| CN1630716A (zh) * | 2001-12-07 | 2005-06-22 | 杰龙公司 | 人胚胎干细胞衍生的造血细胞 |
| GB2398783A (en) * | 2003-02-26 | 2004-09-01 | Antonio Lanzavecchia | A method for producing immortalised human B memory lymphocytes |
| KR100912994B1 (ko) * | 2004-04-05 | 2009-08-21 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Ｎｋｇ２ｄ의 조절 |
| EP3456191A1 (en) * | 2008-06-27 | 2019-03-20 | Merus N.V. | Antibody producing non-human mammals |
| US9428732B2 (en) * | 2011-12-05 | 2016-08-30 | Primorigen Biosciences, Inc. | Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof |
| EP4253409A3 (en) * | 2012-04-17 | 2023-12-06 | University of Washington through its Center for Commercialization | Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof |
| CN104046593A (zh) * | 2013-03-14 | 2014-09-17 | 浙江大学 | 一种低免疫原性的人细胞及其制备方法 |
| US10034463B2 (en) * | 2014-01-24 | 2018-07-31 | Children's Medical Center Corporation | High-throughput mouse model for optimizing antibody affinities |
| WO2016094679A1 (en) * | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| EP3294342A4 (en) * | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| US12642852B1 (en) * | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| KR20240095477A (ko) * | 2017-01-13 | 2024-06-25 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 면역조작된 만능 세포 |
| WO2018140890A1 (en) * | 2017-01-29 | 2018-08-02 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
-
2018
- 2018-03-20 EP EP18771866.3A patent/EP3601528A4/en active Pending
- 2018-03-20 CN CN201880032723.6A patent/CN110637083A/zh active Pending
- 2018-03-20 CN CN202411279640.0A patent/CN119120363A/zh active Pending
- 2018-03-20 CA CA3094322A patent/CA3094322A1/en active Pending
- 2018-03-20 AU AU2018239320A patent/AU2018239320B2/en active Active
- 2018-03-20 JP JP2019552206A patent/JP2020509780A/ja active Pending
- 2018-03-20 WO PCT/US2018/023288 patent/WO2018175390A1/en not_active Ceased
- 2018-03-30 US US16/495,318 patent/US20200095543A1/en not_active Abandoned
-
2022
- 2022-10-05 JP JP2022160907A patent/JP7731579B2/ja active Active
-
2023
- 2023-02-03 US US18/164,502 patent/US20230313131A1/en active Pending
-
2025
- 2025-01-23 AU AU2025200450A patent/AU2025200450A1/en active Pending
- 2025-08-13 JP JP2025134751A patent/JP2025169335A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022188202A (ja) | 細胞並びにその使用方法及び製造方法 | |
| JP7649258B2 (ja) | 癌を治療するための組成物および方法 | |
| JP6866988B2 (ja) | 誘導された樹状細胞およびその使用 | |
| US9907820B2 (en) | Polyclonal gamma delta T cells for immunotherapy | |
| US10059923B2 (en) | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors | |
| JP2021530999A5 (enExample) | ||
| JP2020108398A (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| US20050238626A1 (en) | Antigen specific T cell therapy | |
| JP2023501388A5 (enExample) | ||
| EP3475413A1 (en) | Genetically modified t lymphocytes | |
| WO2019154313A1 (zh) | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 | |
| JP2023532917A (ja) | Ｂ細胞のｂ２ｍ遺伝子座を編集するための方法および組成物 | |
| Brehm et al. | Humanized mice in translational immunology | |
| CN117106061B (zh) | 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用 | |
| CN117987435A (zh) | 氧依赖性嵌合抗原受体表达及其应用 | |
| US20190307800A1 (en) | Methods for off-the-shelf-tumor immunotherapy using allogeneic t-cell precursors | |
| Arjomandnejad et al. | CAR-T regulatory (CAR-Treg) cells: engineering and applications. Biomedicines 2022; 10: 287 | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| CN117736300A (zh) | 靶向巨细胞病毒pp65的T细胞受体和表达其的T细胞及应用 | |
| US20230272431A1 (en) | Methods and compositions for editing the b2m locus in b cells | |
| US20250025499A1 (en) | T cell immunotherapy for hematologic malignancies having an sf3b1 mutation | |
| EP2953644B1 (en) | Induced dendritic cells and uses thereof | |
| WO2025232819A1 (en) | Immunotherapies using engineered cells for enhanced bone marrow homing | |
| WO2025231213A2 (en) | Modified b cells and methods for use thereof | |
| Arjomandnejad et al. | eScholarship@ UMassChan |